Pharmaceutical Technology24 天
NT-219 by Purple Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of ...
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And ...
Pharmaceutical Technology1 个月
CM-24 by Purple Biotech for Non-Small Cell Lung Cancer: Likelihood of Approval
The company’s IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both NK cells and T cells to demonstrate a robust, localized immune response within the tumor ...